French Evaluation Group Avastin Versus Lucentis

• Age ≥ 50 years old
• Affected by neovascular retrofoveal AMD whatever the subtype, unilateral or bilateral (the eye included will be chosen by the investigator and the patient);
• Best corrected VA for the studied eye ranging between 20/32 (6.3/10) and 20/320 (0.6/10) with ETDRS scale
• Size of lesion \< 12 disk area
• In case of occult neovessels, proof required of recent development of the lesion: loss of VA of at least 5 letters ETDRS (equivalent one line) in the last 3 months OR appearance of a subretinal heamorrhage OR increase in the size of the lesion (> 10%) using fluoresceinic angiography during the last month by comparison with the last 3 months OR appearance of OCT criteria of macular oedema type, serous separation of neuro-epithelium, separation of the pigmented epithelial during the last month
• Effective birth control for sexually active female
• Signed informed consent.

Exclusion Criteria:

• Previous or actual treatment with intravitreal injection of an anti-VEGF drug (ranibizumab, bevacizumab or pegaptanib) in the studied eye
• Other healing treatment in the studied eye during the last 3 months before the first injection
• Medical history of photocoagulation in the studied eye
• Involvement in another clinical study (studied eye and/or the other eye)
• Subretinal haemorrhage reaching the fovea centre, with a size > 50% of the lesion area
• Fibrosis or retrofoveal retinal atrophy in the studied eye
• Retinal pigment epithelial tear reaching the macula in the studied eye
• Choroidal neovascularisation not related to a DMLA in the studied eye
• Medical history of intravitreal medical device in the studied eye
• Active or suspected ocular or peri-ocular infection
• Serious active intra-ocular inflammation in the studied eye
• Medical history of auto-immune or idiopathic uveitis
• Proved diabetic retinopathy
• Intra-ocular pressure ≥ 25 mmHg despite two topical hypotonic treatments
• Medical history of intra-ocular surgery within 2 months before the first injection in the studied eye
• Aphakia or lack of lens capsule (not removed by YAG laser) in the studied eye
• Any illness or ocular condition that would require an intra-ocular surgery in the studied eye within 12 months after the inclusion
• Known hypersensitivity to ranibizumab, bevacizumab, or another drug composite of the medicinal products used; allergy to fluorescein, indocyanin green, anaesthetic eye drops
• Arterial hypertension that is not controlled by an appropriate treatment
• Previous or actual treatment with systemic administration of bevacizumab
• Follow up not possible during 12 months
• No affiliation to the French national health insurance program.